Huadong Medicine to buy back shares, reduce capital

Huadong Medicine will repurchase and cancel 284,200 restricted shares from 28 employees who are no longer eligible or met performance criteria. This action, approved by the board on November 20, 2025, and shareholders on December 09, 2025, aims to reduce the company's total share count.

The repurchased shares are priced at CNY 22.85 per share, with funding from the company's own funds. This will decrease the total shares from 1,754,021,048.00 to 1,753,736,848.00, consequently reducing the registered capital by the same amount.

Creditors are invited to submit claims within 45 days of this announcement if they wish to request debt repayment or guarantees. The company will continue to honor valid debts. Claims can be submitted via mail, email, or in person at the company's Hangzhou office.